Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
9 min read
Generium ZAO Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Generium ZAO: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
GE Healthcare Technologies, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GE Healthcare Technologies, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ratio
Latest Hotspot
9 min read
GC Biopharma Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for GC Biopharma Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Galderma SA (Switzerland) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Galderma SA (Switzerland): pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
FutureGen Biopharmaceutical (Beijing) Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for FutureGen Biopharmaceutical (Beijing) Co., Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and
Latest Hotspot
9 min read
Fujian Haixi New Drug Creation Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Fujian Haixi New Drug Creation Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outrea
Latest Hotspot
9 min read
Fujian Cosunter Pharmaceutical Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Fujian Cosunter Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outrea
Latest Hotspot
8 min read
FluoGuide A/S Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for FluoGuide A/S: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
Eyebiotech Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Eyebiotech Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Exelixis, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Exelixis, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
Evopoint Biosciences Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for Evopoint Biosciences Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationa
Latest Hotspot
9 min read
European Organisation for Research & Treatment of Cancer Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist — 27 Aug 2026 Edition
27 August 2026
2026 BD opportunity scan for European Organisation for Research & Treatment of Cancer: pipeline stage, evidence package, IP risk, deal precedent, financial si